NYSEAMERICAN:SYN Synthetic Biologics (SYN) Stock Price, News & Analysis Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume57,700 shsAverage Volume197,338 shsMarket Capitalization$16.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Synthetic Biologics alerts: Email Address Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Synthetic Biologics Stock (NYSEAMERICAN:SYN)Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.Read More Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. SYN Stock News HeadlinesSeptember 12, 2024 | finance.yahoo.comTwist Bioscience Achieves LEED Certification for Sustainable Operations and MaintenanceSeptember 12, 2024 | finance.yahoo.comGenScript Appoints New Board Members to Drive Global GrowthSeptember 16, 2024 | DTI (Ad)I want to be very real with youListen, I don’t come at my readers this direct very often, but here goes nothing: There is one strategy that has helped change my life and I’d like to think it has changed the lives of some of my readers, too. We’ve had success stories but I won’t even show you here because I don’t want you to get unrealistic expectations since individual results do vary. But the point is, this thing is the real deal. There’s a reason I consider it my flagship, even with all the market advantages I’ve discovered in recent years.September 11, 2024 | finance.yahoo.comNanoSyrinx secures funds to develop biologic therapeuticsSeptember 10, 2024 | markets.businessinsider.comTelesis Bio Plans to Delist its Securities from The Nasdaq Stock MarketSeptember 5, 2024 | finance.yahoo.comElutia Announces First Patient Implant of EluPro™, the World’s First Drug-Eluting BioEnvelope for Cardiac Pacemakers and NeurostimulatorsSeptember 5, 2024 | markets.businessinsider.comNoble Financial Sticks to Its Hold Rating for MustGrow Biologics (MGROF)September 3, 2024 | markets.businessinsider.comTruist Financial Sticks to Its Buy Rating for AbSci (ABSI)September 16, 2024 | DTI (Ad)I want to be very real with youListen, I don’t come at my readers this direct very often, but here goes nothing: There is one strategy that has helped change my life and I’d like to think it has changed the lives of some of my readers, too. We’ve had success stories but I won’t even show you here because I don’t want you to get unrealistic expectations since individual results do vary. But the point is, this thing is the real deal. There’s a reason I consider it my flagship, even with all the market advantages I’ve discovered in recent years.September 3, 2024 | msn.comArthritis Patients More Likely to Stick With BiosimilarsSeptember 1, 2024 | reuters.comFederal Regulation of Psychedelic TherapiesAugust 30, 2024 | yahoo.comMore information from the Synthetic Turf CouncilAugust 29, 2024 | bizjournals.comHumacyte co-founder now CEO of Durham startupAugust 27, 2024 | finance.yahoo.comTwist Bioscience to Present at Baird Global Healthcare Conference 2024August 26, 2024 | ca.news.yahoo.comUpdated COVID-19 vaccines will be available in Texas soon. Here’s when you can get oneAugust 26, 2024 | usnews.comOpenAI Supports California AI Bill Requiring 'Watermarking' of Synthetic ContentAugust 26, 2024 | finance.yahoo.comSynthetic Data Generation Market Surpasses USD 3.79 By 2032 Driven Due To Escalating Demand for Data Security and PrivacyAugust 25, 2024 | msn.comMorgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ StocksSee More Headlines Receive SYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Synthetic Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2021Today9/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:SYN CUSIPN/A CIK894158 Webwww.syntheticbiologics.com Phone(301) 417-4364Fax301-417-4367Employees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,270,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-26.14% Return on Assets-22.74% Debt Debt-to-Equity RatioN/A Current Ratio4.14 Quick Ratio4.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.95 per share Price / Book0.21Miscellaneous Outstanding Shares15,844,000Free Float15,503,000Market Cap$16.16 million OptionableNot Optionable Beta1.38 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Steven A. Shallcross CPA (Age 61)CEO, CFO, Treasurer, Corp. Sec. & Director Comp: $976.91kDr. Frank Tufaro Ph.D. (Age 67)Chief Operating Officer Vincent I. PerroneDirector of Corp. CommunicationDr. Vince WacherHead of Product and Corp. Devel.Dr. Michael KalekoSr. VP of R&DMs. Lara M. GuzmanSr. Director of Project OperationsMore ExecutivesKey CompetitorsAileron TherapeuticsNASDAQ:ALRNAffimedNASDAQ:AFMDIO BiotechNASDAQ:IOBTKronos BioNASDAQ:KRONAcerus PharmaceuticalsOTCMKTS:TRLPFView All Competitors SYN Stock Analysis - Frequently Asked Questions How were Synthetic Biologics' earnings last quarter? Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) released its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.10. When did Synthetic Biologics' stock split? Synthetic Biologics shares reverse split on the morning of Monday, July 25th 2022. The 1-10 reverse split was announced on Monday, July 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Synthetic Biologics? Shares of SYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Synthetic Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Synthetic Biologics investors own include Synergy Pharmaceuticals (SGYP), Tonix Pharmaceuticals (TNXP), Agenus (AGEN), Palatin Technologies (PTN), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE) and This page (NYSEAMERICAN:SYN) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synthetic Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synthetic Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.